NCT02643550 2023-05-12Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckInnate PharmaPhase 1/2 Completed143 enrolled
NCT03794544 2022-02-24Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerMedImmune LLCPhase 2 Completed84 enrolled 17 charts